Halozyme Therapeutics HALO Work in process
Work in process at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InventoryWorkInProcessNetOfReserves.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's work in process.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's work in process?
- Halozyme Therapeutics (HALO) reported work in process of $35.04M in Q1 2026.
- How has Halozyme Therapeutics's work in process changed year-over-year?
- Halozyme Therapeutics's work in process decreased by 4.4% year-over-year, from $36.65M to $35.04M.
- What is the long-term trend for Halozyme Therapeutics's work in process?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's work in process has grown at a -1.7% compound annual growth rate (CAGR), from $33.74M to $30.92M.
- What does work in process mean?
- Partially completed goods currently in the manufacturing process, including materials, labor, and overhead costs incurred to date.